Altimmune (ALT) Experiences a Steady Decline Amid a Volatile Market

In the most recent trading session, Altimmune (NYSE: ALT) witnessed a modest decline of 2.69 % during a 24‑hour period that ended at 02:46 AM Central Europe on Saturday, 24 November 2026. The stock, currently priced at approximately USD 2.12 on major exchanges, has seen its valuation erode further since the end of the previous month, registering a decline of 31.97 % over the past month.

Market Overview

  • Current Trading Price: USD 2.12
  • Shares Outstanding: 194.5 million
  • Market Capitalization: USD 433.8 million
  • Volume (Last 24 hours): USD 6.7 million worth of shares traded

The 200‑day simple moving average (SMA) sits at USD 3.34, indicating that the current price is well below its long‑term average. In a broader 52‑week perspective, Altimmune’s highest price of USD 6.44 was recorded on 23 January 2026, while the 52‑week low was USD 2.15 on 22 October 2026.

Altimmune’s recent performance can be contextualized by examining the movements of other companies within the same sector and broader market:

  • Contango Silver & Gold (CTGO) – Down 3.53 %, trading at USD 14.45; market cap USD 503.2 million.
  • Sierra (BSRR) – Up 1.92 %, trading at USD 41.74; market cap USD 507.1 million; P/E ratio 11.64.
  • Delcath (DCTH) – Up 0.34 %, trading at USD 14.42; market cap USD 510.1 million; P/E ratio 2,410.
  • Msc Income (MSIF) – Down 0.17 %, trading at USD 11.54; market cap USD 519.2 million; P/E ratio 5.35.
  • Aquestive Therapeutics (AQST) – Up 0.74 %, trading at USD 4.00; market cap USD 512.1 million.

While most peers have posted modest gains, Altimmune remains the outlier, underscoring the volatility that can afflict clinical‑stage biopharmaceutical firms.

Company Background

Altimmune, Inc. is a clinical‑stage biopharmaceutical company headquartered in the United States. Its portfolio focuses on peptide‑based therapeutics designed to address a range of metabolic and hepatic conditions, including obesity, non‑alcoholic fatty liver disease (NASH), chronic hepatitis B, and other liver disorders. The company operates on a global scale, engaging both patients and healthcare professionals, and maintains an online presence at www.altimmune.com . Altimmune’s shares are listed on the Nasdaq exchange.

Altimmune’s current trajectory highlights the challenges faced by companies in the early‑stage drug development arena. As the market continues to scrutinize both clinical outcomes and financial metrics, investors will likely remain vigilant about how the company navigates regulatory milestones, clinical trial results, and potential partnerships.